Explore

Rapid Read Rapid Read
FDA Approves Moderna's mRNA-Based Flu Vaccine Amid Funding Cuts

FDA Approves Moderna's mRNA-Based Flu Vaccine Amid Funding Cuts

The FDA has approved Moderna's mRNA-based flu vaccine for adults aged 50 and older, marking a significant milestone as it is the first time mRNA technology, previously used in COVID-19 vaccines, has been approved for seasonal flu prevention. This approval comes at a time when federal funding for mRNA vaccine research has been significantly reduced, raising concerns about the future of mRNA technology development. Smaller companies and universities, which rely heavily on government funding for clinical trials, may face challenges in advancing new vaccines due to these cuts. Despite the funding issues, Moderna has managed to fund its research independently, allowing the flu vaccine to be available within weeks.
Rapid Read Rapid Read
FDA Approves Moderna's mRNA-Based Flu Vaccine for Adults Over 50

FDA Approves Moderna's mRNA-Based Flu Vaccine for Adults Over 50

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based seasonal influenza vaccine, mFLUSIVA, for adults aged 50 and older. This marks the first flu shot utilizing the same mRNA technology as Moderna's COVID-19 vaccine to be approved in the U.S. The approval, granted on August 5, is aimed at older populations who are more vulnerable to severe flu complications. Clinical trials demonstrated that mFLUSIVA outperformed standard-dose flu vaccines, showing a 26.6% higher efficacy. However, its use in adults aged 65 and older remains under 'accelerated approval,' pending further confirmatory studies.
Trendline Trendline
FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market

FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market

FDA Approves Moderna's mFLUSIVA, Strengthening Its Position in mRNA Vaccine Market
Rapid Read Rapid Read
Nanotechnology Advances COVID-19 Vaccine Delivery with Lipid Nanoparticles

Nanotechnology Advances COVID-19 Vaccine Delivery with Lipid Nanoparticles

The COVID-19 pandemic has accelerated the development of vaccines, with nanotechnology playing a crucial role in enhancing vaccine delivery systems. Lipid nanoparticles (LNPs) have been instrumental in addressing challenges associated with traditional vaccine approaches, such as immunogenicity and stability. These nanoparticles have become the backbone of mRNA vaccines like Pfizer-BioNTech and Moderna, improving vaccine stability, enabling precise cellular delivery, and reducing side effects. The chapter discusses the transformative role of nanotechnology in vaccine delivery, focusing on mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA) vaccines. Innovations in thermostable formulations, mucosal delivery systems, and AI-driven vaccine design are paving the way for more accessible and effective immunization strategies.
Trendline Trendline
Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment

Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment

Axsome Therapeutics Reports Significant Growth in Second Quarter 2026 with New Alzheimer's Treatment
Rapid Read Rapid Read
FDA Proposes New Rule on Food Additives, Delays Ultra-Processed Foods Definition

FDA Proposes New Rule on Food Additives, Delays Ultra-Processed Foods Definition

The FDA has proposed a new rule requiring food manufacturers to notify the agency of all ingredients brought to market under the GRAS pathway. This move aims to close a regulatory loophole that has allowed companies to use certain additives without FDA oversight. However, the Trump administration has delayed defining 'ultra-processed foods,' a promise made earlier this year. The proposal comes amid significant foodborne illness outbreaks in the U.S., including cyclosporiasis and salmonella. The new rule would formalize the GRAS framework as a mandatory notification system, impacting how new and existing food additives are regulated.
Reuters Reuters
Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

By Sneha S K and Amina Niasse NEW YORK, Aug 10 (Reuters) - Hims & Hers Health posted a wider-than-expected second-quarter loss on Monday as the telehealth company's shift to branded weight-loss drugs drove up costs, sending its shares down 6% in extended trading.
Rapid Read Rapid Read
Taylor Farms Recalls Jalapeño Products Amid Salmonella Outbreak

Taylor Farms Recalls Jalapeño Products Amid Salmonella Outbreak

Taylor Farms has initiated a recall of over a dozen jalapeño-containing products from grocery stores across 26 states due to a salmonella outbreak. The affected items include dips, salsas, and guacamole sold at major retailers like Walmart, Target, and Whole Foods. The recall follows a cyclosporiasis outbreak linked to Taylor Farms, with jalapeños sourced from Coast Citrus Distributors in Sinaloa, Mexico identified as the contamination source.
Reuters Reuters
Taylor Farms recalls salsa and guacamole from Walmart, Kroger over salmonella risk

Taylor Farms recalls salsa and guacamole from Walmart, Kroger over salmonella risk

Aug 9 (Reuters) - Taylor Farms said on Sunday it was recalling prepared food items containing jalapenos from retailers, including Walmart, Kroger and Whole Foods in some states, over concerns about potential salmonella contamination.
Vox Vox
The strange reason flu shots have been so hard to improve

The strange reason flu shots have been so hard to improve

America finally has an mRNA flu shot. Now comes the fight to actually use it.
Rapid Read Rapid Read
At-Home HPV Tests Gain FDA Approval, Offering New Screening Options

At-Home HPV Tests Gain FDA Approval, Offering New Screening Options

The FDA has authorized the first at-home self-collection device for cervical cancer screening, which tests for high-risk strains of Human Papillomavirus (HPV). This development comes amid a decline in cervical cancer screenings in the U.S., with rates dropping from 47% in 2019 to 41% in 2023. The at-home test is designed to increase accessibility, particularly for women in rural areas who are less likely to receive regular screenings. While the test offers a convenient option for those who avoid traditional screenings, it is not a substitute for in-office exams. The at-home kit cannot perform the comprehensive pelvic and clinical exams necessary to detect other potential health issues. It is intended as a bridge to care for women who are not being screened at all.
Reuters Reuters
Michigan salad warnings ease, but cyclospora keeps shoppers and grocers on edge

Michigan salad warnings ease, but cyclospora keeps shoppers and grocers on edge

By Danielle Kaye and Waylon Cunningham NEW YORK, Aug 8 (Reuters) - Michigan health officials cleared shoppers to put lettuce back in their grocery carts, but anxiety about cyclosporiasis is lingering in the grocery aisles, with some produce sellers supplied by local farms saying customers have